好酸球性 2 型喘息における白血球プロファイリング:全身性 IL-5 ターゲティングの影響
The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
調査の概要
状態
条件
詳細な説明
Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.
The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Skåne County
-
Lund、Skåne County、スウェーデン、22185
- The Lung and Allergy Clinic, Skåne University Hospital (SUS)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.
説明
Inclusion Criteria:
- Clinical diagnosis of asthma (the asthma patient arms)
- Eligible for Mepolizumab treatment as per the country-specific prescribing information (the arms with Mepolizumab)
Exclusion criteria:
- Any diagnosed infection (all arms)
- Previous history of lung disease, chronic inflammatory condition, atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling (Healthy non-asthma control subjects)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:CROSS_SECTIONAL
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Asthma patients initiating Mepolizumab treatment
Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
他の名前:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
他の名前:
|
|
Asthma patients already on Mepolizumab treatment
Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
他の名前:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
他の名前:
|
|
Asthma patients without Mepolizumab treatment
Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections |
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
他の名前:
|
|
Healthy non-asthmatic control subjects
Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Blood Eosinophil Marker Expression
時間枠:Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Basophil Marker Expression
時間枠:Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Leukocyte Composition
時間枠:Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Blood T Lymphocyte Marker Expression
時間枠:Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio). |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood B Lymphocyte Marker Expression
時間枠:Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Leukocyte Total Cell Counts
時間枠:Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
Routine clinical laboratory total leukocyte counts in peripheral blood |
Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Forced Expiratory Volume in 1 Second (FEV1)
時間枠:Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Expiratory Volume, 1s; (FEV1). |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Forced Vital Capacity (FVC)
時間枠:Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Vital Capacity (FVC) |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Exhaled FeNo
時間枠:Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
Fractional exhaled NO will be measured at multiple flows |
Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。